Rapidly giving intravenous fluid to prevent or treat shock (fluid resuscitation) is one of the commonest treatments given to critically ill patients. Current guidelines recommend crystalloid solutions but it is unknown whether any particular crystalloid is better than others. This trial will determine whether the use of one of two crystalloid fluids, saline or PlasmaLyte, reduces the risk of organ injuries, such as kidney failure, and improves patients chances of surviving critically illness.
Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment For Women Of Child-bearing Age With Psychotic Symptoms Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$210,480.00
Summary
Schizophrenia is a devastating illness urgently requiring a new treatment approach. We have discovered that estrogen is an effective treatment for women with schizophrenia and are currently trialling a safer Selective Estrogen Receptor Modulator (SERM) known as brain estrogen� in postmenopausal women with schizophrenia. Regulatory permission is now available to trial the SERM in younger women, and we seek to extend our current SERM study into child bearing age women with schizophrenia.
From Brain Maps To Mechanisms: Modeling The Pathophysiology Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
My Fellowship will develop a framework that integrates brain imaging data with mathematical models of the brain to help understand the mechanisms responsible for schizophrenia. By linking functional Magnetic Resonance Imaging (fMRI) measurements to models of their underlying causes, the work may lead to new treatments that target the specific dysfunction in individuals with this debilitating brain disorder.
Prevention Of Complications In Type 2 Diabetes By Using ICT To Optimise Self-management
Funder
National Health and Medical Research Council
Funding Amount
$849,181.00
Summary
The impact of the diabetes epidemic on individuals and society is severe but can be reduced by improving diabetes self-management. Conducted in partnership with Diabetes Australia (Queensland, Victoria, WA) and Roche Diagnostics, this research will evaluate the 'real world' implementation of a telehealth program, already successfully trialled, which has the potential to provide a low cost and effective program to a large number of Australians with type 2 diabetes.